Biomarkers of Renal Function: Towards Clinical Actionability

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 3, 2017, Pages 481-492

  Binnenmars, S Heleen ^a   Hijmans, R S ^a   Navis, G ^a   de Borst, M H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERVENTION STUDY; KIDNEY FUNCTION; META ANALYSIS (TOPIC); METABOLISM; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; KIDNEY; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; BIOMARKERS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85026811776     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.765     Document Type: Review

References (78)

1. Seufert, W.D. Uroscopy. Can. Med. Assoc. J. 154, 1711 (1996).
2. Porter, K.A. Effect of homologous bone marrow injections in x-irradiated rabbits. Br. J. Exp. Pathol. 38, 401–412 (1957).
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
4. Maisel, A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J. Am. Coll. Cardiol. 58, 1890–1892 (2011).
5. Robinson, W.H., Lindstrom, T.M., Cheung, R.K. & Sokolove, J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat. Rev. Rheumatol. 9, 267–276 (2013).
6. Brück, K. et al. CKD prevalence varies across the European general population. J. Am. Soc. Nephrol. 27, 2135–2147 (2016).
7. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2, 1–138 (2012).
8. Susantitaphong, P. et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am. J. Kidney Dis. 61, 430–439 (2013).
9. Haase-Fielitz, A., Haase, M. & Devarajan, P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann. Clin. Biochem. 51, 335–351 (2014).
10. Hjortrup, P.B., Haase, N., Wetterslev, M. & Perner, A. Clinical review: Predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit. Care 17, 211 (2013).
11. Ho, J. et al. Urinary, plasma, and serum biomarkers' utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis. Am. J. Kidney Dis. 66, 993–1005 (2015).
12. Lin, X., Yuan, J., Zhao, Y. & Zha, Y. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis. J. Nephrol. 28, 7–16 (2015).
13. Liu, Y. et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis. Am. J. Kidney Dis. 62, 1058–1067 (2013).
14. Shao, X. et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One 9, e84131 (2014).
15. Su, Y., Gong, Z., Wu, Y., Tian, Y. & Liao, X. Diagnostic value of urine tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 for acute kidney injury: a meta-analysis. PLoS One 12, e0170214 (2017).
16. Yong, Z., Pei, X., Zhu, B., Yuan, H. & Zhao, W. Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials. Sci. Rep. 7, 41012 (2017).
17. Kim, S. et al. Is plasma neutrophil gelatinase-associated lipocalin a predictive biomarker for acute kidney injury in sepsis patients? A systematic review and meta-analysis. J. Crit. Care 33, 213–223 (2016).
18. Zhang, A. et al. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis. Crit. Care 20, 41 (2016).
19. Alge, J.L. & Arthur, J.M. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin. J. Am. Soc. Nephrol. 10, 147–155 (2015).
20. Meisner, A., Kerr, K.F., Thiessen-Philbrook, H., Coca, S.G. & Parikh, C.R. Methodological issues in current practice may lead to bias in the development of biomarker combinations for predicting acute kidney injury. Kidney Int. 89, 429–438 (2016).
21. ® test system: decision summary. .
22. Hoste, E.A.J. et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol. Dial. Transplant 29, 2054–2061 (2014).
23. Bihorac, A. et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am. J. Respir. Crit. Care Med. 189, 932–939 (2014).
24. Kashani, K. et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013).
25. Vijayan, A. et al. Clinical use of the urine biomarker [TIMP-2] × [IGFBP7] for acute kidney injury risk assessment. Am. J. Kidney Dis. 68, 19–28 (2016).
26. Bucaloiu, I.D., Kirchner, H.L., Norfolk, E.R., Hartle, J.E. 2nd & Perkins, R.M. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 81, 477–485 (2012).
27. Xue, J.L. et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J. Am. Soc. Nephrol. 17, 1135–1142 (2006).
28. Haase, M. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 57, 1752–1761 (2011).
29. Coca, S.G. et al. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J. Am. Soc. Nephrol. 25, 1063–1071 (2014).
30. Feng, Y., Zhang, Y., Li, G. & Wang, L. Relationship of cystatin-C change and the prevalence of death or dialysis need after acute kidney injury: a meta-analysis. Nephrology (Carlton). 19, 679–684 (2014).
31. Schaub, J.A. & Parikh, C.R. Biomarkers of acute kidney injury and associations with short- and long-term outcomes. F1000Research 5, (2016).
32. Hall, I.E. et al. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin. J. Am. Soc. Nephrol. 6, 2740–2749 (2011).
33. Chen, C. et al. Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome. Clin. J. Am. Soc. Nephrol. 11, 1536–1544 (2016).
34. Arthur, J.M. et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. Kidney Int. 85, 431–438 (2014).
35. Kidney Disease: Improving Global Outcomes (KDIGO), C. W. G. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 3, 1–150 (2013).
36. Gansevoort, R.T. et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 80, 93–104 (2011).
37. Astor, B.C. et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 79, 1331–1340 (2011).
38. Matsushita, K. et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 3, 514–525 (2015).
39. Fried, L.F. & Lewis, J. Albuminuria is not an appropriate therapeutic target in patients with CKD: The Con View. Clin. J. Am. Soc. Nephrol. 10, 1089–1093 (2015).
40. Endre, Z.H. Using biomarkers for acute kidney injury: barriers and solutions. Nephron. Clin. Pract. 127, 180–184 (2014).
41. Nkuipou-Kenfack, E., Zurbig, P. & Mischak, H. The long path towards implementation of clinical proteomics: Exemplified based on CKD273. Proteomics. Clin. Appl. (2016) doi:10.1002/prca.201600104 [Epub ahead of print].
42. Pena, M.J. et al. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol. Dial. Transplant 30 (suppl. 4), iv86–95 (2015).
43. Critselis, E. & Lambers Heerspink, H. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol. Dial. Transplant. 31, gfv062 (2015).
44. Merchant, M.L. Can the urinary peptidome outperform creatinine and albumin to predict renal function decline? J. Am. Soc. Nephrol. 26, 1760–1761 (2015).
45. Rossing, K. et al. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 19, 1283–1290 (2008).
46. Schanstra, J.P. et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J. Am. Soc. Nephrol. 26, 1999–2010 (2015).
47. Lindhardt, M. et al. Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 6, e010310 (2016).
48. Heerspink, H.J.L., Kröpelin, T.F., Hoekman, J., Zeeuw, D. de & Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J. Am. Soc. Nephrol. 26, 2055–64 (2015).
49. Inker, L.A. et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am. J. Kidney Dis. 64, 74–85 (2014).
50. Jun, M. et al. Assessing the validity of surrogate outcomes for ESRD: A meta-analysis. J. Am. Soc. Nephrol. 26, 2289–2302 (2015).
51. Lambers Heerspink, H.J. et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am. J. Kidney Dis. 64, 860–866 (2014).
52. Shlipak, M.G. et al. Cystatin C versus creatinine in determining risk based on kidney function. N. Engl. J. Med. 369, 932–943 (2013).
53. Inker, L.A. et al. Filtration markers as predictors of ESRD and mortality: individual participant data meta-analysis. Clin. J. Am. Soc. Nephrol. 12, 69–78 (2017).
54. Zhou, L.-T. et al. Are urinary tubular injury markers useful in chronic kidney disease? A systematic review and meta analysis. PLoS One 11, e0167334 (2016).
55. Li, W.-J. et al. Cardiac troponin and C-reactive protein for predicting all-cause and cardiovascular mortality in patients with chronic kidney disease: a meta-analysis. Clinics (Sao Paulo) 70, 301–311 (2015).
56. Michos, E.D. et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann. Intern. Med. 161, 491–501 (2014).
57. Schaub, J.A. et al. Amino-terminal pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and meta-analysis. JACC Heart Fail. 3, 977–989 (2015).
58. Tangri, N. et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 315, 164–74 (2016).
59. Webster, A.C., Nagler, E.V., Morton, R.L. & Masson, P. Chronic kidney disease. Lancet 389, 1238–1252 (2017).
60. Moynihan, R., Glassock, R. & Doust, J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ 347, f4298–f4298 (2013).
61. Hsu, C. et al. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int. 91, 196–203 (2017).
62. Floege, J., Mak, R.H., Molitoris, B.A., Remuzzi, G. & Ronco, P. Nephrology research—the past, present and future. Nat. Rev. Nephrol. 11, 677–87 (2015).
63. Gibson, R.S. Principles of Nutritional Assessment (Oxford, UK: Oxford University Press, 2005).
64. D'Elia, L. et al. Meta-analysis of the effect of dietary sodium restriction with or without concomitant renin-angiotensin-aldosterone system-inhibiting treatment on albuminuria. Clin. J. Am. Soc. Nephrol. 10, 1542–1552 (2015).
65. McMahon, E.J., Campbell, K.L., Bauer, J.D. & Mudge, D.W. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst. Rev. CD010070 (2015).
66. Vegter, S. et al. Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165–173 (2012).
67. Lambers Heerspink, H.J. et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 82, 330–337 (2012).
68. Maroni, B.J., Steinman, T.I. & Mitch, W.E. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 27, 58–65 (1985).
69. Keyzer, C.A. et al. Plasma vitamin D level and change in albuminuria and egfr according to sodium intake. Clin. J. Am. Soc. Nephrol. 10, 2119–2127 (2015).
70. Keyzer, C.A. et al. Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: the ViRTUE-CKD Trial. J. Am. Soc. Nephrol. 28, 1296–1305 (2017).
71. Borst, M.H. de et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J. Am. Soc. Nephrol. 24, 1863–1871 (2013).
72. Boxma, P.Y. et al. Vitamin K intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS One 7, e47991 (2012).
73. Keyzer, C.A. et al. Vitamin K status and mortality after kidney transplantation: a cohort study. Am. J. Kidney Dis. 65, 474–483 (2015).
74. Schlieper, G. et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J. Am. Soc. Nephrol. 22, 387–395 (2011).
75. Xin, W., Mi, S. & Lin, Z. Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials. Cardiovasc. Ther. 34, 441–449 (2016).
76. Wolf, M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 82, 737–747 (2012).
77. Kieneker, L.M. et al. Urinary potassium excretion and risk of developing hypertension: the prevention of renal and vascular end-stage disease study. Hypertens. (Dallas, Tex. 1979) 64, 769–776 (2014).
78. Humalda, J.K. et al. Concordance of dietary sodium intake and concomitant phosphate load: implications for sodium interventions. Nutr. Metab. Cardiovasc. Dis. 26, (2016).